You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Human Performance Optimization
SBC: HVMN Inc. Topic: SOCOM17C001During altitude-induced hypoxia, operator cognitive and physical capacity degrades, compromising individual and team performance. Cognitive degradation is linked to falling brain energy levels, increased reliance on anaerobic energy production and lactate accumulation. Ketones are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies demonstrated that ...
STTR Phase II 2019 Department of DefenseSpecial Operations Command -
Southeast Xlerator Network
SBC: XLERATEHEALTH, LLC Topic: RThe Southeast XLerator Network proposes to create a networked and easily accessible regional technology transfer accelerator hub (“XLerator Hub” or “Hub”) to share best practices, disseminate education content, and offer products, services, facilities and other resources connected through both physical and online platforms for innovators and trainees in the Southeast IDeA states. Led by XL ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Naloxone Nasal Spray Development
SBC: ANTIOP, INC. Topic: NIDADESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens
SBC: SILVER LAKE RESEARCH CORPORATION Topic: NIAIDPROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms
SBC: NeuroSigma, Inc. Topic: 101DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
HUCBC modulation of Alzheimer's-like pathology and behavioral changes
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NIADESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Detect and Avoid Certification Environment for Unmanned Air Vehicles (UAVs)
SBC: RDRTEC INCORPORATED Topic: N18AT007The objective of this project is to develop a comprehensive suite of tools, called the DAA Radar Software Suite and Simulation (DAA-RSSS), that supports future Navy procurement and certification of non-cooperative sensor technologies for Detect And Avoid (DAA) as well as develop plans to support EO/IR sensors as the non-cooperative sensor as informed by FAA activities in developing Minimum Operati ...
STTR Phase II 2019 Department of DefenseNavy -
Transformation Accelerated through Redesign, Guidance, and Enhanced Training (TARGET)
SBC: TIER 1 PERFORMANCE SOLUTIONS LLC Topic: N17AT017As submarine threats from adversary countries continue to rise, the U.S. Navy must maintain and expand its anti-submarine warfare (ASW) capabilities. Warfighter readiness is the linchpin of the Navy’s ASW strategy, but the complexity of the ASW domain necessitates time-consuming training, and practical experiences to transfer those skills to the operational environment. Innovative training appro ...
STTR Phase II 2019 Department of DefenseNavy -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health